Parth Shah MD

#CGAT@Dartmouth #EDIT@CGAT #DartmouthHemeOnc #DFCI #CART #BMT #OmicsinMedicine #Heterogeneityenthusiast, #genomicsinmedicine.tweets my own. not org

[Parth Shah MD @TCellRxDoc]

@dtbergman @IvyLorena_Md

[Drew T Bergman, MD @dtbergman]

Excited to pave the way for further prospective investigation w/ this observational work, towards better selection in this highly pre-treated patient population without many other options.

Thanks to the whole team: @ZofiaCieslak @TCellRxDoc and many more at @DartmouthCancer.

[Parth Shah MD @TCellRxDoc]

Excited to get this data out there! Lets get tarlatamab patient selection always correct! https://t.co/Tu6NCBhrAu Phenomenal work by
@dtbergman and @ZofiaCieslak in with our lung group at the @DartmouthCancer @ShahlabDCC @KeisukeShirai7 @IvyLorena_Md @NidhiPShahMD

[Parth Shah MD @TCellRxDoc]

@CSMIA_Official how can immigration lines be taking almost 5-10 min per person ?! This is so far behind any airport of this size ! We have been standing in line for more than 90 min already with only 20-30 people ahead of us!

[Parth Shah MD @TCellRxDoc]

@rabonour1 @RahulBanerjeeMD @End_myeloma As precision myeloma therapeutics takes hold - we may be talking about this more than ever before.

[Parth Shah MD @TCellRxDoc]

@bdermanmd The options seem confusing when the brand name tests are also myeloma panels

[Parth Shah MD @TCellRxDoc]

This is an important view point. Cancer is often an emotion and we are used to taking risks in cancer that we do not for most public health. Although I think MCED will at one point change healthcare - we CANNOT abandon the principles of screening tools.

[Eric Topol @EricTopol]

Let's talk 🧵about the results of a new, large trial of a multi-cancer early detection blood test called Galleri, which costs $949, that enrolled 35,878 participants in the US and Canada aged 50+. Here is the registration: https://t.co/HdxApX6sHg
These are the headlines

[Parth Shah MD @TCellRxDoc]

@bdermanmd Completely agreed ! Take down the dex as soon as possible !

[Saurabh Zanwar @ZanwarSaurabh]

Highly recommended!! I did this fellowship last year and it was a perfect fit for me. Worth putting in the extra year. Gained a lot of amazing experience in MGCS, POEMS, AL with @ADispenzieri @MorieGertz @myelomaMD et al. Gave me time and mentorship to get grants/publications in.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Come work with us!!

cc @MadhavDhodapkar @AJPortuguese @DimaDanai @RichaThakurMD and many more not on Twitter!

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: https://t.co/dmQRuFVugC. #mmsm

[Parth Shah MD @TCellRxDoc]

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center | JCO Precision Oncology https://t.co/PwcLxYmG3N

Awesome to see this finally out! More on the way to redefine molecular care !

[Michael Jain @MichaelDJain]

Interesting, I always wondered why heme biosynthesis comes up as a pathway involved in therapy resistance. Looks like it modulates apoptosis resistance.

[Arvind Suresh @ArvindSuresh1]

Thank you to everyone at @DartmouthCancer who supported this work, as well as @ASH_hematology for funding!

@TCellRxDoc @TheBloodMD

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Congrats @RascheLeo et al for this excellent @BloodJournal work about better understanding EMD in #MMsm

As a myeloma specialist, the ball of plasma cells in that visual abstract is more scary to me than the CML bunny will ever be!!! 😱

[Vincent Rajkumar @VincentRK]

Just out: Results of the CEPHEUS trial presented by @szusmani @MSKCancerCenter at the Plenary Session @Myeloma_Society

Significant improvement in PFS with Dara-VRd compared to VRd in patients who were transplant ineligible or deferred. Median age 70.

1/

[Vincent Rajkumar @VincentRK]

Outcomes with quadruplet induction and risk adapted maintenance in myeloma. Major progress.

Dr. Nisha Joseph, @AjayNookaMD @SagarLonialMD et al @WinshipAtEmory
@BloodCancerJnl

https://t.co/A3rEtXzdTC

[Parth Shah MD @TCellRxDoc]

So much work by so many people ! Go @CGAT @DartmouthCancer @DPLM

Excited to make WES /WTS standard in somatic sequencing across institutions !

https://t.co/QghohtiN2e

@LJTafeMD @NidhiPShahMD

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Nice #MMsm work with provocative conclusion in @ASTCT_Journal by Wesson @DimaDanai @Abdallah81MD @hhashmi87 @NausheenAhmedMD and more!

With so many "0%" incidences for new toxicities in weeks 3-4 following BCMA CAR-T, can 🇺🇸 REMS be shortened some day?

https://t.co/b1yk8zbrA2

[Vincent Rajkumar @VincentRK]

This is the second of two back to back papers that show the value of belantamab in myeloma.